Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial.

Background: Multiple sclerosis is associated with muscle stiffness, spasms, pain, and tremor. Much anecdotal evidence suggests that cannabinoids could help these symptoms. Our aim was to test the notion that cannabinoids have a beneficial effect on spasticity and other symptoms related to multiple s...

Descripción completa

Detalles Bibliográficos
Publicado en:Lancet Vol. 362; no. 9395; pp. 1517 - 1527
Autores principales: Zajicek J, Fox P, Sanders H, Wright D, Vickery J, Nunn A, Thompson A, Zajicek, John, Fox, Patrick, Sanders, Hilary, Wright, David, Vickery, Jane, Nunn, Andrew, Thompson, Alan
Formato: clinical trial research tables/charts Journal Article
Publicado: Lancet 11/8/2003
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=106576709&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 106576709
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        01406736
        LAN
      jtl: Lancet
      issn: 01406736
      maglogo: N
    pubinfo:
      dt: 11/8/2003
      vid: 362
      iid: 9395
      pid: 1297
      pub: Lancet
      place: Philadelphia, Pennsylvania
    artinfo:
      ui:
        106576709
        106576709
        NLM14615106
        2005032340
        10.1016/s0140-6736(03)14738-1
        NLM14615106
        106576709
      ppf: 1517
      ppct: 10
      formats:
        fmt:
          – @attributes:
              type: T
          – @attributes:
              type: P
      tig:
        atl: Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial.
      aug:
        au:
          Zajicek J
          Fox P
          Sanders H
          Wright D
          Vickery J
          Nunn A
          Thompson A
          Zajicek, John
          Fox, Patrick
          Sanders, Hilary
          Wright, David
          Vickery, Jane
          Nunn, Andrew
          Thompson, Alan
        affil: Peninsula Medical School, Plymouth, UK
      sug:
        subj:
          Cannabis Therapeutic Use
          Multiple Sclerosis Drug Therapy
          Muscle Spasticity Drug Therapy
          Barthel Index
          Cannabis Adverse Effects
          Clinical Trials
          Confidence Intervals
          Data Analysis Software
          Double-Blind Studies
          Female
          Kruskal-Wallis Test
          Male
          Middle Age
          Nonparametric Statistics
          One-Way Analysis of Variance
          Physical Mobility
          Questionnaires
          Random Assignment
          Scales
          Treatment Outcomes
          United Kingdom
          Funding Source
          Human
          Middle Aged: 45-64 years
          Female
          Male
      ab: Background: Multiple sclerosis is associated with muscle stiffness, spasms, pain, and tremor. Much anecdotal evidence suggests that cannabinoids could help these symptoms. Our aim was to test the notion that cannabinoids have a beneficial effect on spasticity and other symptoms related to multiple sclerosis.Methods: We did a randomised, placebo-controlled trial, to which we enrolled 667 patients with stable multiple sclerosis and muscle spasticity. 630 participants were treated at 33 UK centres with oral cannabis extract (n=211), Delta9-tetrahydrocannabinol (Delta9-THC; n=206), or placebo (n=213). Trial duration was 15 weeks. Our primary outcome measure was change in overall spasticity scores, using the Ashworth scale. Analysis was by intention to treat.Findings: 611 of 630 patients were followed up for the primary endpoint. We noted no treatment effect of cannabinoids on the primary outcome (p=0.40). The estimated difference in mean reduction in total Ashworth score for participants taking cannabis extract compared with placebo was 0.32 (95% CI -1.04 to 1.67), and for those taking Delta9-THC versus placebo it was 0.94 (-0.44 to 2.31). There was evidence of a treatment effect on patient-reported spasticity and pain (p=0.003), with improvement in spasticity reported in 61% (n=121, 95% CI 54.6-68.2), 60% (n=108, 52.5-66.8), and 46% (n=91, 39.0-52.9) of participants on cannabis extract, Delta9-THC, and placebo, respectively.Interpretation: Treatment with cannabinoids did not have a beneficial effect on spasticity when assessed with the Ashworth scale. However, though there was a degree of unmasking among the patients in the active treatment groups, objective improvement in mobility and patients' opinion of an improvement in pain suggest cannabinoids might be clinically useful.
      pubtype: Academic Journal
      doctype:
        clinical trial
        research
        tables/charts
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N